EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?

Laure Sayyed Kassem iD, Aman Rajpal, Margarita Victoria Barreiro, Faramarz Ismail-Beigi

Journal of Diabetes · 2023-10 · 15 (10) · 817-837

DOI: 10.1111/1753-0407.13446 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Diabetes, online erschienen am 31.07.2023. Verfasst von Laure Sayyed Kassem und 3 weiteren Autor:innen. Beteiligte Einrichtung: Case Western Reserve University, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin-Secreting Cells. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 diabetes (T2DM) is a complex metabolic disorder manifested by hyperglycemia, insulin resistance, and deteriorating beta‐cell function. A way to prevent progression of the disease might be to enhance beta‐cell function and insulin secretion. However, most previous studies examined beta‐cell function while patients were using glycemia‐lowering agents without an adequate period off medications (washout). In the present review we focus on studies with a washout period. We performed a literature search (2010 to June 2021) using beta‐cell function and enhancement. The evidence shows that beta‐cell function can be enhanced. Bariatric surgery and very low calorie diets show improvement in beta‐cell function in many individuals. In addition, use of glucagon‐like peptide‐1 receptor agonists for prolonged periods (3 years or more) can also lead to improvement of beta‐cell function. Further research is needed to understand the mechanisms leading to improved beta‐cell function and identify agents that could enhance beta‐cell function in patients with T2DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Insulin-Secreting CellsHumansHypoglycemic AgentsBariatric SurgeryInsulin ResistanceInsulin SecretionGlucagon-Like Peptide-1 Receptor AgonistsBlood GlucoseCaloric RestrictionInsulin

Stichwörter der Autor:innen

beta-cell massbeta-cell replicationbeta-cell survivaldisposition indexinsulin resistanceβ细胞复制β细胞存活β细胞数量处置指数胰岛素抵抗

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsBlood GlucoseInsulin

Autor:innen und Institutionen

  • Case Western Reserve University, Cleveland, Ohio, USA.
  • Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
  • University Hospitals of Cleveland, Cleveland, Ohio, USA.

ORCID-Profile: Laure Sayyed Kassem

Zitieren

APA

Sayyed Kassem, L., Rajpal, A., Barreiro, M. V., & Ismail-Beigi, F. (2023). Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?. Journal of Diabetes, 15(10), 817-837. https://doi.org/10.1111/1753-0407.13446

Vancouver

Sayyed Kassem L, Rajpal A, Barreiro MV, Ismail-Beigi F. Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?. Journal of Diabetes. 2023;15(10):817-837. doi:10.1111/1753-0407.13446

BibTeX
@article{SayyedKassem2023,
  author = {Sayyed Kassem, Laure and Rajpal, Aman and Barreiro, Margarita Victoria and Ismail-Beigi, Faramarz},
  title = {Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?},
  journal = {Journal of Diabetes},
  year = {2023},
  volume = {15},
  number = {10},
  pages = {817--837},
  doi = {10.1111/1753-0407.13446}
}
Kostenlos starten →